Zostavax — The Original Live-Attenuated Shingles Vaccine
A single-dose weakened varicella-zoster virus vaccine.
- 2006: Approved (first shingles vaccine)
- 1: Doses required (single subcutaneous shot)
- 51%: Initial efficacy (shingles prevention)
- Live: Vaccine type (attenuated Oka strain)
What Zostavax contains
A live, weakened form of varicella-zoster virus.
Dose is far stronger than the childhood chickenpox shot.
It nudges aging immunity to recognize the virus again.
How it performs at baseline
Shingles risk drops by roughly half at the start.
Postherpetic neuralgia risk falls by about two-thirds.
Efficacy is notably lower in adults over 70.
Zostavax Limitations — Waning Protection and Restricted Use
Protection erodes with age and cannot reach everyone.
- ~14%: Efficacy at year 8 (steep decline)
- No: Immunocompromised use (live virus risk)
- 2020: Retired in US (discontinued by maker)
- None: Booster option (single dose only)
Protection wanes quickly
Efficacy drops sharply within the first five years.
By year eight, meaningful protection is largely gone.
Who cannot receive it
Live virus makes it unsafe for weakened immune systems.
Cancer, transplant, and HIV patients must avoid it.
Shingrix — Recombinant Subunit, Two-Dose Protection
A lab-made viral protein plus a strong adjuvant.
- 2017: Approved (second-generation vaccine)
- 2: Doses required (two–six months apart)
- >90%: Initial efficacy (shingles prevention)
- Non-live: Vaccine type (glycoprotein E subunit)
What Shingrix contains
A single viral surface protein, not a live virus.
An adjuvant system boosts the immune response strongly.
Why efficacy jumps so high
Two doses build layered, durable immune memory.
Efficacy stays above 90% even in older adults.
Shingrix Durability — High Efficacy Years Later
Protection barely fades across nearly a decade.
- ~85%: Efficacy at year 7 (still very high)
- Slow: Decline rate (gradual, not steep)
- >90%: Age 70+ efficacy (consistent across ages)
- 10 yr: Follow-up studies (ongoing surveillance)
Why durability matters
Shingles risk rises with age, so lasting cover counts.
A flat efficacy curve means fewer breakthrough cases.
Long-term trial data
Multi-year follow-up confirms efficacy stays near 90%.
No steep drop-off has been observed through year ten.
Comparative Conclusion — Shingrix Is Now Preferred
Higher efficacy, longer duration, and broader safety.
- +40pt: Efficacy edge (Shingrix vs Zostavax)
- Years: Durability edge (far slower decay)
- Immunocomp.: Safety edge (Shingrix only option)
- Shingrix: CDC recommendation (preferred since 2018)
Efficacy and durability
Shingrix starts higher and declines far more slowly.
Zostavax fades to near-negligible protection within a decade.
Safety in vulnerable patients
Shingrix contains no live virus, so it is safe.
Zostavax remains contraindicated for immunocompromised patients.